Myriad Genetics (MYGN) Q2 2025: Oncology Drives 14% HCT Volume Surge as Strategy Pivots to Cancer Care Continuum
Myriad Genetics’ Q2 marks a strategic inflection, with oncology-led hereditary cancer testing (HCT) volumes up 14% and a sharpened focus on the cancer care continuum (CCC) as the new growth engine. Operational execution improved across core franchises, while prenatal headwinds and payer dynamics shaped near-term results. Guidance was raised, with management signaling stepped-up urgency and capital allocation discipline to accelerate profitable growth into 2026.
Summary
- Oncology Focus Intensifies: Company pivots strategy and investment toward high-growth cancer testing segments.
- Operational Discipline Emerges: Margin expansion and cost controls support improved profitability despite legacy headwinds.
- 2026 Trajectory in Focus: Raised guidance and new partnerships set the stage for acceleration in core and adjacent markets.
Performance Analysis
Myriad Genetics delivered a mixed but strategically significant quarter, with total revenue rising modestly on a reported basis but underlying growth of 5% when adjusting for UnitedHealthcare’s GeneSight coverage change and the EndoPredict divestiture. Average revenue per test increased 2% year-over-year, reflecting pricing discipline and payer coverage wins, especially in prenatal and hereditary cancer segments. Oncology was the clear standout, with hereditary cancer testing (HCT) volumes up 14% in the oncology channel and unaffected HCT volumes returning to growth after workflow and EMR integration improvements.
GeneSight, the flagship mental health test, rebounded to 5% volume growth after Q1’s commercial reorganization, though overall pharmacogenomics revenue was down due to payer headwinds. Prenatal volumes declined 7% year-over-year due to a now-resolved order management system issue, but management expects a rebound in the second half. Gross margin expanded by 140 basis points to 71.5%, driven by mix, payer traction, and operational efficiency. Adjusted EBITDA rose 24% year-over-year, underscoring the cash-generating potential as operating leverage improves.
- Oncology Volume Acceleration: HCT volumes in oncology up 14%, fueled by workflow and EMR improvements.
- Prenatal Headwinds Transitory: Order management system fix positions prenatal for volume recovery in Q3 and Q4.
- Margin Expansion Signals Model Leverage: 140bps gross margin improvement highlights scalable cost structure and payer wins.
Despite the headline GAAP loss from a non-cash $317 million impairment (due to lower market cap), underlying trends point to a business regaining momentum in its core franchises and executing on its updated strategy.
Executive Commentary
"The core of our updated strategy is to drive accelerated growth and profitability by focusing on the cancer care continuum. There are three strategic pillars to support its achievement."
Sam Raha, President and Chief Executive Officer
"Even with the modest overall Q2 revenue growth, we were able to expand our gross margins by 140 basis points to 71.5%. This year-over-year improvement reflects favorable test mix, expanding payer coverage and lab efficiencies, and is a testament to the power of our scalable business model."
Scott Loeffler, Chief Financial Officer
Strategic Positioning
1. Cancer Care Continuum (CCC) as Growth Anchor
Myriad’s updated strategy centers on the cancer care continuum, leveraging its heritage in hereditary cancer and HRD (homologous recombination deficiency, a key biomarker in oncology) to expand into adjacent, high-growth segments like therapy selection, comprehensive genomic profiling, immuno-oncology response monitoring, and MRD (minimal residual disease, a test for cancer recurrence risk). Strategic partnerships, such as Pathomic for AI-enabled prostate cancer diagnostics, will accelerate portfolio breadth and market reach.
2. Disciplined Expansion in Prenatal and Mental Health
Prenatal and mental health remain growth contributors but with disciplined resource allocation. Recent launches—Prequel NIPS at 8 weeks and expanded Foresight carrier screening—are gaining traction, and the early access launch of the “first gene” combined screen could expand the prenatal addressable market in 2026. GeneSight growth is being restored through targeted account focus and payer wins, including new Medicaid and commercial coverage.
3. Financial Discipline and Capital Flexibility
Cost control and margin management are central to the new playbook, with gross margin leadership and a focus on growing revenue faster than operating expenses. The new $200 million Orbamed term loan replaces a more restrictive ABL facility, providing multi-year liquidity and investment capacity for strategic priorities, particularly in R&D for oncology.
4. Execution Rigor and Talent Upgrade
Management is signaling a step-change in execution urgency and operational rigor, with a commitment to “elevated discipline” and domain expertise. Periodic portfolio reviews and a willingness to partner rather than build in-house are notable cultural shifts that aim to drive focus and accelerate time-to-market for new tests.
Key Considerations
This quarter marks a visible pivot in both strategy and operational cadence. Investors should weigh the following:
Key Considerations:
- Oncology as Primary Growth Vector: The shift to CCC is supported by strong provider relationships, payer coverage, and a reputation for quality, but success in new segments will require rapid execution and differentiated offerings.
- Payer Environment Improving: 49 new coverage or policy expansions year-to-date, especially in prenatal and mental health, underpin a more stable and maturing reimbursement landscape.
- Operational Leverage Emerging: Margin expansion and EBITDA growth signal the model’s scalability, but sustained improvement depends on volume recovery in prenatal and continued payer traction.
- Strategic Partnerships Gain Emphasis: The Pathomic collaboration and a stated openness to external R&D signal a pragmatic approach to portfolio buildout and capital allocation.
- Guidance Credibility Hinges on Execution: Raised outlook is tied to resolving operational friction and delivering on new product launches, particularly in prenatal and MRD.
Risks
Execution risk remains high as Myriad enters new oncology segments where entrenched competitors and payer adoption hurdles persist. Prenatal recovery depends on flawless operational execution post-system fix. The UnitedHealthcare GeneSight coverage loss continues to pressure pharmacogenomics and could influence broader payer sentiment if not reversed. Interest expense from the new term loan raises the bar for incremental return on R&D and commercial investments.
Forward Outlook
For Q3, Myriad expects:
- Seasonally slower quarter, with Q3 2024 as a tough comp due to a $9 million prior period benefit not repeating.
- Continued margin strength and operational recovery in prenatal and unaffected HCT.
For full-year 2025, management raised guidance:
- Revenue: $818 million to $828 million
- Gross margin: 69.5% to 70%
- Adjusted EBITDA: $27 million to $33 million
- Adjusted EPS: $(0.02) to $0.02
Management highlighted several factors that underpin the guide:
- Volume recovery in prenatal and unaffected HCT expected in the second half.
- Incremental payer wins and pricing improvements to sustain average revenue per test.
Takeaways
Myriad’s Q2 signals a decisive pivot to oncology-driven growth, with margin gains and payer traction supporting a raised outlook.
- Oncology Execution Is the Decisive Lever: Sustained HCT volume growth and new product launches in CCC will determine whether Myriad can outpace market growth and offset legacy headwinds.
- Prenatal and Mental Health Remain Growth Contributors: Recovery in prenatal volumes and continued GeneSight payer gains are necessary to deliver on full-year guidance and long-term targets.
- Strategic Partnerships and R&D Allocation Will Shape Portfolio Expansion: Investors should watch for additional deals and clarity on KPIs at future updates, particularly around MRD and comprehensive genomic profiling.
Conclusion
Myriad Genetics enters the second half of 2025 with renewed strategic clarity, operational discipline, and a raised outlook anchored in oncology momentum. The balance of execution in prenatal, mental health, and new cancer testing launches will determine whether the company can deliver on its multi-year growth and profitability ambitions.
Industry Read-Through
Myriad’s pivot to the cancer care continuum mirrors a broader diagnostics industry trend toward specialization and portfolio breadth in high-value, reimbursed testing segments. The emphasis on payer engagement, digital workflow integration, and strategic partnerships is increasingly the norm for diagnostics players seeking scale and margin expansion. MRD, comprehensive genomic profiling, and AI-enabled diagnostics are fast becoming table stakes for oncology labs. Competitors with legacy prenatal or pharmacogenomics exposure face similar operational and reimbursement volatility, reinforcing the need for focused capital allocation and execution rigor.